ArticleVeterinary and comparative oncology2017
Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination.
Article in Veterinary and comparative oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Preclinical study of an optimized AAV cancer vaccine in a spontaneous canine model of oral melanoma.Molecular therapy. Oncology · 2026Article
- Cytokine-Enhanced Vaccine as Surgery Adjuvant Treatment for Spontaneous Canine Melanoma: Comparison of Two Intralesional Procedures for Local Disease Control.Veterinary and comparative oncology · 2026Article
- Clinical evaluation of HuDo-CSPG4 DNA electroporation as adjuvant treatment for canine oral malignant melanoma: comparison of two vaccination protocols.The veterinary quarterly · 2025Article
- PD-L1, PD-1, and CTLA-4 mRNA In Situ Expression by Canine Oral Melanoma Cells and Immune Cells of the Tumour Microenvironment.Veterinary and comparative oncology · 2025Article
- Clinical Trials of Cancer Immunogene Therapies in Companion Animals: An Update (2017-2024).Veterinary sciences · 2025Review
- Influence of the extent of cervical lymph node dissection and lymph nodes metastases on prognosis in a cohort of dogs with oral malignant melanoma treated by surgical resection and adjuvant anti-CSPG4 electrovaccination: a retrospective study on 77 cases.Frontiers in veterinary science · 2025Article
- APAVAC Immunotherapy for the Adjuvant Treatment of a Canine Mucosal Melanoma.Veterinary sciences · 2024Article
- Establishment of Primary Cell Cultures from Canine Oral Melanomas via Fine-Needle Aspiration: A Novel Tool for Tumorigenesis and Cancer Progression Studies.Animals : an open access journal from MDPI · 2024Article
- Risk stratification scheme based on the TNM staging system for dogs with oral malignant melanoma centered on clinicopathologic presentation.Frontiers in veterinary science · 2024Article
- The diagnostic yield of preoperative screening for oral cancer in dogs over 15 years, part 1: locoregional screening.Journal of the American Veterinary Medical Association · 2023Article
- The diagnostic yield of preoperative screening for oral cancer in dogs over 15 years, part 2: distant screening.Journal of the American Veterinary Medical Association · 2023Article
- A chimeric human/dog-DNA vaccine against CSPG4 induces immunity with therapeutic potential in comparative preclinical models of osteosarcoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Potential Promises and Perils of Human Biological Treatments for Immunotherapy in Veterinary Oncology.Veterinary sciences · 2023Review
- Article
- Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial.Journal for immunotherapy of cancer · 2022Article
- Treatment of Canine Oral Melanomas: A Critical Review of the Literature.Veterinary sciences · 2022Review
- Prognostic impact of bone invasion in canine oral malignant melanoma treated by surgery and anti-CSPG4 vaccination: A retrospective study on 68 cases (2010-2020).Veterinary and comparative oncology · 2022Article
- Canine melanoma: A review of diagnostics and comparative mechanisms of disease and immunotolerance in the era of the immunotherapies.Frontiers in veterinary science · 2022Review
- Canine Melanoma Immunology and Immunotherapy: Relevance of Translational Research.Frontiers in veterinary science · 2022Article
- Difference in outcome between curative intent vs marginal excision as a first treatment in dogs with oral malignant melanoma and the impact of adjuvant CSPG4-DNA electrovaccination: A retrospective study on 155 cases.Veterinary and comparative oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Reported post-surgery 1-year survival rate for oral canine malignant melanoma (cMM) is around 30%; novel treatments are needed as the role of adjuvant chemotherapy is unclear. This prospective study regards adjuvant electrovaccination with human chondroitin sulfate proteoglycan-4 (hCSPG4)-encoded plasmid in 23 dogs with resected II/III-staged CSPG4-positive oral cMM compared with 19 dogs with resected only II/III-staged CSPG4-positive oral cMM. Vaccination resulted in 6-, 12-, 18- and 24-month survival rate of 95.6, 73.9, 47.8 and 30.4%, respectively [median survival time (MST) 684 days, range 78-1694, 8 of 23 dogs alive] and 6-, 12-, 18- and 24-month disease-free interval (DFI) rate of 82.6, 47.8, 26.1 and 17.4%, respectively (DFI 477 days, range 50-1694). Non-vaccinated dogs showed 6-, 12-, 18- and 24-month survival rate of 63.2, 26.3, 15.8 and 5.3%, respectively (MST 200 days, range 75-1507, 1 of 19 dogs alive) and 6-, 12-, 18- and 24-month DFI rate of 52.6, 26.3, 10.5 and 5.3%, respectively (DFI 180 days, range 38-1250). Overall survival and DFI of vaccinated dogs was longer in those <20 kg. In vaccinated and non-vaccinated dogs local recurrence rate was 34.8 and 42%, respectively while lung metastatic rate was 39 and 79%, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.